Sai Life Sciences Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹602.14 crore, reflecting a quarter-on-quarter *(QoQ) increase of 8.21 per cent from ₹556.46 crore. This corresponds to a year-on-year *(YoY) growth of 3.91 per cent.
Operating Profit
Operating Profit stands at ₹176.55 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.68 per cent from ₹179.56 crore. This corresponds to a year-on-year *(YoY) growth of 12.04 per cent.
PBDT
PBDT stands at ₹184.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.52 per cent from ₹178.26 crore. This corresponds to a year-on-year *(YoY) growth of 18.08 per cent.
Profit Before Tax
Profit Before Tax stands at ₹139.23 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.76 per cent from ₹134.18 crore. This corresponds to a year-on-year *(YoY) growth of 17.20 per cent.
Net Profit
Net Profit stands at ₹104.24 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.85 per cent from ₹100.38 crore. This represents a 18.09 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Sai Life Sciences Ltd News
Sai Life Sciences Ltd Earnings
- YOY
- QOQ
Sai Life Sciences Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Sai Life Sciences Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Sai Life Sciences Ltd Financial Reports
Sai Life Sciences Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Sai Life | 2.62% | -1.50% | 7.16% | 16.51% | 32.85% | 60.21% |
| Wockhardt | 14.62% | 23.87% | 42.46% | 55.02% | 38.06% | 38.58% |
| Emcure Pharma | -2.00% | -2.69% | -5.34% | 16.88% | 18.04% | 25.21% |
| Acutaas Chemical | 4.52% | 7.45% | 17.29% | 43.19% | 77.13% | 179.27% |
| Piramal Pharma | -1.03% | -3.88% | 7.55% | 12.72% | -6.71% | -16.15% |
| Neuland Labs. | 1.84% | 1.94% | 5.78% | 30.33% | 2.99% | 46.18% |
| Astrazeneca Phar | 0.19% | -1.41% | 7.77% | -1.44% | -4.23% | -6.92% |
Company Info
Company Information
Chairman & Exec. Director : Ranga Raju Kanumuri
Managing Director & CEO : Krishnamraju Kanumuri
Independent Non Exe. Director : Ramesh Iyer
Independent Non Exe. Director : Suchita Sharma
Independent Non Exe. Director : Dinesh V Patel
Whole Time Director & CFO : SIVARAMAKRISHNAN CHITTOR
Company Sec. & Compli. Officer : RUNA KUMAR